Researchers at Mount Auburn Hospital in Massachusetts found that angioplasty patients who received bivalirudin had fewer but more severe bleeding episodes than those treated with eptifibatide. Among 345 patients who received eptifibatide, 20 had bleeding events, while 10 events were reported among 660 patients in the bivalirudin group, and in each group, seven of the episodes were considered severe.
Bivalirudin and eptifibatide's bleeding risks are evaluated in study
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||